OTCMKTS:JCRRF JCR Pharmaceuticals (JCRRF) Stock Price, News & Analysis $4.70 0.00 (0.00%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$4.70▼$4.7050-Day Range$4.30▼$5.2252-Week Range$4.30▼$4.30VolumeN/AAverage Volume267 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get JCR Pharmaceuticals alerts: Email Address Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About JCR Pharmaceuticals Stock (OTCMKTS:JCRRF)JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.Read More JCRRF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JCRRF Stock News HeadlinesSeptember 2, 2024 | americanbankingnews.comJCR Pharmaceuticals Co., Ltd. (OTCMKTS:JCRRF) Short Interest Down 7.3% in AugustJuly 19, 2024 | businesswire.comJCR Pharmaceuticals Highlights Innovative Gene Therapy Research at the 7th International Forum of Lysosomal DisordersSeptember 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.May 25, 2024 | finance.yahoo.comModalis Therapeutics Corporation (4883.T)March 19, 2024 | finance.yahoo.comJCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with AlexionMarch 2, 2024 | morningstar.comJCR Pharmaceuticals Co Ltd 4552February 29, 2024 | finance.yahoo.comJCR Pharmaceuticals Celebrates Rare Disease Day 2024 and Highlights Its Commitment to the Rare Disease CommunityFebruary 14, 2024 | finance.yahoo.comJCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage DisordersSeptember 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.January 25, 2024 | markets.businessinsider.comJCR Pharmaceuticals earnings preview: what Wall Street is expectingJanuary 25, 2024 | finance.yahoo.comJCR Pharmaceuticals to Present at the 20th Annual WORLDSymposium™ 2024December 21, 2023 | finance.yahoo.comJCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® TechnologyDecember 21, 2023 | finance.yahoo.comJCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy CollaborationDecember 15, 2023 | finance.yahoo.comU.S. FDA Grants Orphan Drug Designation to JR-441 for the Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)November 13, 2023 | msn.comJCR Pharmaceuticals doses first patient in MPS IIIA trialOctober 24, 2023 | markets.businessinsider.comJCR Pharmaceuticals earnings preview: what to expectSeptember 29, 2023 | finance.yahoo.comJCR Pharmaceuticals Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)September 28, 2023 | marketwatch.comJCR Pharmaceuticals Shares Jump After It Raises Earnings GuidanceSee More Headlines Receive JCRRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for JCR Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:JCRRF CUSIPN/A CIKN/A Webwww.jcrpharm.co.jp Phone81 7 9732 8591FaxN/AEmployees879Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Shin Ashida (Age 81)Chairman, CEO & President Yoshihiro OtaDirector of Accounting Department & Corporate Strategy Department (Finance)Yutaka HondaSenior Corporate Officer, Executive Director of Administration Div. & Director of Human ResourcesHiroyuki FukuyaDirector of Legal Affairs Department - Administration DivisionToru Ashida (Age 56)Senior VP of Sales & Administration, Executive Director of Sales Division and Director Ryutaro MakinoDirector of Marketing Dept. & Group Manager of Product Planning - Marketing Dept. for Sales Div.Katsuya Nishino (Age 68)Executive Vice President Hiroshi Yoshimoto (Age 73)Senior Advisor Takayo EgawaCorporate Officer & Director of International Affairs OfficeMr. Hiroyuki Sonoda Ph.D. (Age 46)VP of Research & Corporate Strategy, Executive Director of Research Division and Director More ExecutivesKey CompetitorsAstraZenecaOTCMKTS:AZNCFDaiichi SankyoOTCMKTS:DSNKYDechra PharmaceuticalsOTCMKTS:DCHPFKyowa KirinOTCMKTS:KYKOFMayne Pharma GroupOTCMKTS:MAYNFView All Competitors JCRRF Stock Analysis - Frequently Asked Questions How have JCRRF shares performed this year? JCR Pharmaceuticals' stock was trading at $9.04 at the start of the year. Since then, JCRRF stock has decreased by 48.0% and is now trading at $4.70. View the best growth stocks for 2024 here. How do I buy shares of JCR Pharmaceuticals? Shares of JCRRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:JCRRF) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JCR Pharmaceuticals Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share JCR Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.